Anti-hCD19-CD3

InvivoGen Kontakt z doradcą
Bispecific antibody against human CD19 and human CD3

Anti-hCD19-CD3 is a bispecific antibody that recognizes two human cell markers: hCD19, which is expressed on the surface of B cells, and hCD3 which is part of the T cell receptor. This antibody features Blinatumomab single-chain variable fragments (scFv) joined by a glycine-serine linker. These two scFvs have been cloned from the anti-hCD19 (clone HD37) and anti-hCD3 (clone L2K-07) monoclonal antibodies [1,2]. Blinatumomab is used for the treatment of refractory acute lymphocytic leukemia (ALL) in clinics. By binding to hCD3 and hCD19, Blinatumomab engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [2]. Blinatumomab does not cross‑react with CD3 and CD19 from mice, rats, or dogs [3].

Anti-hCD19-CD3 bispecific antibody can be used for fine-tuning studies of B cell contact-dependent killing and T cell activation/proliferation.

Negative control antibodies are also available from InvivoGen: Anti-hCD19-βGal and Anti-βGal-hCD3.

References:

  1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
  2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7. 
  3. Trivedi A. et al., 2017. Clinical Pharmacology and Translational Aspects of Bispecific Antibodies. Clin Transl Sci. 10(3):147-162.

Podobne produkty

Anti-hVEGF-hIgA2

Anti-hVEGF-hIgA2

InvivoGen
Więcej
Anti-mTIGIT

Anti-mTIGIT

InvivoGen
Więcej
Anti-hIFN-γ

Anti-hIFN-γ

InvivoGen
Więcej